Related Experiment Video
Updated: Jul 15, 2026

Analytical Techniques for Assaying Nitric Oxide Bioactivity
Published on: June 18, 2012
Nitrate cessation profiles in men wishing to use sildenafil citrate
Alexander Müller1, Jeremy Shelton, Marilyn Parker
1Department of Urology, Weill Medical College of Cornell University, New York Presbyterian Hospital, New York, New York 10021, USA.
Objectives:
To define the likelihood of nitrate users wishing to use sildenafil citrate being permitted by their nitrate-prescribing physicians to cease nitrate use, and to attempt to derive predictors of a "no" response to this request.
Methods:
A total of 248 patients with erectile dysfunction were included in this study. All patients using or in possession of nitrates who opted to be treated with sildenafil had letters sent to the nitrate-prescribing physician, asking whether the nitrate could be ceased so as to facilitate sildenafil use.
Results:
Of 248 letters, 236 (95.7%) were answered by the nitrate-prescribing physicians. The types of nitrate use included oral (72 patients), sublingual (150 patients), and transdermal (14 patients); mean patient age was 64 years. To the question, "Would you permit the patient to cease use or possession of nitrate, to facilitate the use of sildenafil," 42% of the physicians (99 of 236) responded "yes." For men who were using oral, transdermal, and as-required sublingual nitrates, 28%, 0, and 53% of letters had a "yes" response. In a multivariable analysis we found five predictors of a "no" response: patient age greater than 65 years, duration of nitrate possession less than 6 months, oral/transdermal nitrate use, sublingual nitrate use more than once per year, and nitrate medication prescribed by a non-cardiology physician.
Conclusions:
We demonstrated that 42% of men with erectile dysfunction who were using nitrates were permitted to discard their nitrates to facilitate sildenafil use, and we identified factors predicting a "no" response to such a request.
Related Concept Videos
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Nitric Oxide Signaling Pathway
Antianginal Drugs: Nitrates and β-Blockers
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...
Antihypertensive Drugs: Vasodilators
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Angina V: Nursing Management